Nystatin Articles
VR776 achieves clinical proof of concept in PE
28 May 2007
Shire to review options after US SPD465 delay
28 May 2007
Wyeth's Lybrel approved by FDA
28 May 2007
Sosei completes AD 923 pharmacokinetic study
28 May 2007
GSK shares slide 5.1% after Avandia linked to CV death risk; firm likely to cut guidance
28 May 2007
Phytopharm's Myogane enters Ph Ib UK study
28 May 2007
IMB suspends sale of nimesulide products
21 May 2007
FDA OKs Nautilus' Ph I Belerofon trial
21 May 2007
Japan stock market week to May 14, 2007
21 May 2007
FDA asks for more data on Emend injection
21 May 2007
Transdermal AD patch impresses in IDEAL trial
21 May 2007
Teva gets generic Omnicef OK, starts shipping
21 May 2007
Cephalon's 1st-qtr income soars to $75M
14 May 2007
Altus starts Ph III trial of ALTU-135
14 May 2007
BioSante in contraceptive deal with Pantarhei
14 May 2007
Valcyte as effective as ganciclovir in CMV
14 May 2007
Bayer and Intendis to promote Yaz for acne
14 May 2007
Novartis
14 May 2007
ViroPharma sets up European subsidiary
14 May 2007
Phoqus Group appoints Richard Mason CEO
7 May 2007
Duramed's Enjuvia gets two FDA appros
7 May 2007
Proteolix licenses CyDex' Captisol
7 May 2007
Pfizer's Celebrex gets UK OK for AS
7 May 2007
EC clears S-P's desloratidine brands
7 May 2007
Cimzia key drug in UCB 2007 R&D update
7 May 2007
Generex in Middle East licensing deal for Oral-lyn
30 April 2007
UCB's Keppra effective in infant seizure study
30 April 2007
Merck & Co launches Januvia in UK
30 April 2007
US FDA approves Merck & Co's Singulair in EIB
30 April 2007
Bayer examines Glucobay in CV prevention
30 April 2007
PCT124 yields promising animal data in DMD
30 April 2007
Actelion's 1st-qtr 2007 loss deepens 179%
30 April 2007
Pharmion's oral azacitidine advances
30 April 2007
Vectura's ED drug impresses in 2nd Ph IIb study
30 April 2007
Schering-Plough 1st-qtr profits leap 55%
30 April 2007
S-P's oral antiplatelet drug to enter Ph III trials
30 April 2007
Merck & Co's 1st-qtr income climbs 12%
30 April 2007
Avalon identifies patient strata biomarkers
23 April 2007
Encouraging Ph IIa data for Allergy Thera's vacc
23 April 2007
FDA faces Plan B law suit for OTC approval
23 April 2007
Lilly's 1st-qtr 2007 earnings drop 39%
23 April 2007
FDA approves Novartis' Reclast for Paget's
23 April 2007
Poniard starts Ph I oral picoplatin study
23 April 2007
India's OTC drug market boom
23 April 2007
Immtech's pafuramidine enters Ph IIb trial
16 April 2007
Stock Commentary - New York week to April 9
16 April 2007
SCLOR starts PKC study of CDT-fenofibrate
16 April 2007
Callisto's Guanilib moves into clincial testing
16 April 2007
Manhattan acquires drug candidates
16 April 2007
Erbitux increases overall survival in SCCHN
16 April 2007
Alkermes submits Vivitrol MAA in UK and Germany
9 April 2007
GSK submits lapatinib NDA in Japan
9 April 2007
Novacea's 4th-qtr 2006 loss widens to $7.8M
9 April 2007
Merck & Co's Januvia gets EC OK
2 April 2007
BioCell's Collagen II passes toxicology tests
2 April 2007
CHR-2797 enters Ph II trial in AML
2 April 2007
BioCryst puts hold on IV Fodosine Ph IIb trial
2 April 2007
Iroko Pharma gets two Merck & Co drugs
2 April 2007
Otsuka's tolvaptan improves ADHF
2 April 2007
Three new drugs get nod from EMEA's CHMP
2 April 2007
S-P's TRA drug meets Ph II endpoints
2 April 2007
Bayer and Novartis in MS drug deal
2 April 2007
Amicus presents strong Ph I Plicera data
26 March 2007
Shire debuts Lialda in USA
26 March 2007
US FDA approves Teva's generic Uniretic
19 March 2007
Ark Thera's 2006 loss up 16%, on R&D costs
19 March 2007
13 new drugs added to Japan's NHI list
19 March 2007
Bentley Pharma's bicalutamide gets Spanish OK
12 March 2007
Australian approval for Encysive's Thelin
12 March 2007
BioCryst and Shionogi accord on peramivir
12 March 2007
Pfizer's maraviroc impresses in HIV trials
12 March 2007
Medical literature supports Bradley's low-dose estrogen
12 March 2007
Barr posts $391M net loss in 4th qtr 2006
12 March 2007
Watson sees a 4th-qtr 2006 net loss of $489M
12 March 2007
Cytogen's 4th-qtr 2006 losses up 85.4%
12 March 2007
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
